Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115878 | 0.90 | LMNA (0.61) | LMNAPOLBCYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL2115875 | 0.90 | LMNA (0.61) | LMNAPOLBCYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL1088276 | 0.82 | CYP2D6 (0.78) | LMNAPOLBCYP2D6SMN1; SMN2CYP3A4 | |
| SCHEMBL16218991 | 0.81 | ALDH1A1 (0.66) | LMNAPOLBSMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL23241265 | 0.80 | LMNA (0.41) | LMNAPOLBCYP2D6SMN1; SMN2CYP3A4 | |
| SCHEMBL5857769 | 0.78 | SIGMAR1 (0.50) | LMNACYP2D6SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL5857768 | 0.78 | SIGMAR1 (0.50) | LMNACYP2D6SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL8192193 | 0.78 | SMN1; SMN2 (0.60) | LMNAPOLBCYP2D6SMN1; SMN2CYP3A4 | |
| SCHEMBL2134536 | 0.77 | SMN1; SMN2 (0.51) | LMNACYP2D6SMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL2609709 | 0.76 | GAA (0.43) | POLBSMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11246850-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-11129806-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11007167-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007166-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10959972-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210023040-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-01-28 | — | — | US | disclosed |
| US-20200345679-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2020-11-05 | — | — | US | disclosed |
| US-20190125710-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20180000770-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2334378-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129806-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | LMNA 3109/4885POLB 2218/4885CYP2D6 814/4885 |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | LMNA 4568/4885POLB 1143/4885CYP2D6 86/4885 |
| US-20190125710-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | LMNA 3109/4885POLB 2218/4885CYP2D6 814/4885 |
| US-20210023040-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | LMNA 3109/4885POLB 2218/4885CYP2D6 814/4885 |
| US-11007167-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | LMNA 3109/4885POLB 2218/4885CYP2D6 814/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | LMNA 4576/4885POLB 1066/4885CYP2D6 83/4885 |
| US-11007166-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | LMNA 3109/4885POLB 2218/4885CYP2D6 814/4885 |
| US-11246850-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | LMNA 3109/4885POLB 2218/4885CYP2D6 814/4885 |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | LMNA 3109/4885POLB 2218/4885CYP2D6 814/4885 |
| US-20180000770-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | LMNA 3109/4885POLB 2218/4885CYP2D6 814/4885 |
| US-10959972-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | LMNA 3109/4885POLB 2218/4885CYP2D6 814/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | LMNA 4568/4885POLB 1143/4885CYP2D6 86/4885 |
| US-20200345679-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | LMNA 3109/4885POLB 2218/4885CYP2D6 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.